Effectiveness of antipsychotic maintenance therapy with quetiapine in comparison with risperidone and olanzapine in routine schizophrenia treatment: Results of a prospective observational trial

European Archives of Psychiatry and Clinical Neuroscience

Volumn 262, Issue 7, 2012, Pages 589-598

  Kilian, Reinhold ^a   Steinert, Tilman ^a   Schepp, Wiltrud ^b   Weiser, Prisca ^a   Jaeger, Susanne ^a   Pfiffner, Carmen ^a   Frasch, Karel ^a   Eschweiler, Gerhard W ^c   Messer, Thomas ^d   Croissant, Daniela ^e   Becker, Thomas ^a   Längle, Gerhard ^c,e  

^a UNIVERSITY OF ULM   (Germany)

^b Bezirksklinikum Regensburg ^*  (Germany)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^d Danuvius Klinik GmbH   (Germany)

^e Klinik für Kinder und Jugendpsychiatrie und Psychotherapie   (Germany)

Author keywords

Antipsychotic maintenance therapy; Observational trial; Olanzapine; Quetiapine; Risperidone; Schizophrenia

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; ARTICLE; DRUG EFFICACY; FEMALE; FOLLOW UP; HOSPITAL READMISSION; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; OUTCOMES RESEARCH; PATIENT COMPLIANCE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOPHARMACOTHERAPY; REGRESSION ANALYSIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; STATISTICAL MODEL; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DIBENZOTHIAZEPINES; FEMALE; HOSPITAL ADMINISTRATION; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RISPERIDONE; SCHIZOPHRENIA; SELECTION BIAS; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84867980467     PISSN: 09401334     EISSN: 14338491     Source Type: Journal    
DOI: 10.1007/s00406-012-0316-9     Document Type: Article

References (33)

1. Komossa K, Rummel-Kluge C, Schmid F et al (2010) Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev (1):CD006625
2. Rummel-Kluge C, Komossa K, Schwarz S et al (2010) Secondgeneration antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. Schizophr Bull
3. Dossenbach M, Pecenak J, Szulc A et al (2008) Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study. J Clin Psychiatry 69(12):1901-1915
4. Dossenbach M, Dyachkova Y, Pirildar S et al (2006) Effects of atypical and typical antipsychotic treatments on sexual function in patients with schizophrenia: 12-month results from the intercontinental schizophrenia outpatient health outcomes (IC-SOHO) study. Eur Psychiatry 21(4):251-258 (Pubitemid 43929245)
5. Dossenbach M, Erol A, el Mahfoud KM et al (2004) Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (ICSOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. J Clin Psychiatry 65(3):312-321
6. Swartz MS, Stroup TS, McEvoy JP et al (2008) What CATIE found: results from the schizophrenia trial. Psychiatry Serv 59(5):500-506
7. Stroup TS, Lieberman JA, McEvoy JP et al (2007) Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Am J Psychiatry 164(3):415-427 (Pubitemid 46513155)
8. Lieberman JA, Stroup TS, McEvoy JP et al (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353(12):1209-1223 (Pubitemid 41345943)
9. de Arce CR, Eding E, Marques-Teixeira J et al (2011) Descriptive analyses of the aripiprazole arm in the risperidone longacting injectable versus quetiapine relapse prevention trial (ConstaTRE). Eur Arch Psychiatry Clin Neurosci. doi: 10.1007/s00406-011-0220-8
10. Johnsen E, Kroken RA, Wentzel-Larsen T et al (2010) Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone. BMC Psychiatry 10:26
11. Moller HJ (2011) How close is evidence to truth in evidencebased treatment of mental disorders? Eur Arch Psychiatry Clin Neurosci. doi:10.1007/s00406-011-0273-8
12. Kay SR, Opler LA, Lindemeyer JP (1989) The positive and negative syndrome scale (PANSS): rationale and standardisation. Br J Psychiatry 155:59-65 (Pubitemid 19270851)
13. American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders, 4th edn, Text Revision edn. American Psychiatric Association, Washington
14. Simpson G, Angus J (1970) A rating scale for extrapyramidal side effects. Acta Psychiatry Scand 212:11-19
15. Lane RD, Glazer WM, Hansen TE et al (1985) Assessment of tardive dyskinesia using the abnormal involuntary movement scale. J Nerv Ment Dis 173(6):353-357 (Pubitemid 15079180)
16. Gaite L, Vázquez-Barquero JL, Arraiga Arrizabalaga A et al (2000) Internal consistency of the Lancashire quality of life profile - EU version (LQoLP-EU) EPSILON study 8. Br J Psychiatry 39(suppl):s49-s54
17. Thompson K, Kulkarni J, Sergejew AA (2000) Reliability and validity of a new medication adherence rating scale (MARS) for the psychoses. Schizophr Res 42(3):241-247 (Pubitemid 30216535)
18. Kaufman A, Lichtenberger E (2002) Assessing adolescent and adult intelligence. Wiley, Hoboken
19. Chisholm D, Knapp M, Knudsen HC et al (2000) Client sociodemographic and service receipt inventory-European version. Br J Psychiatry 177(suppl. 39):S28-S33
20. Andreasen NC, Pressler M, Nopoulos P et al (2010) Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol Psychiatry 67(3):255-262
21. Gardner DM, Murphy AL, O'Donnell H et al (2010) International consensus study of antipsychotic dosing. Am J Psychiatry 167(6):686-693
22. Swanson JM, Hinshaw SP, Arnold LE et al (2007) Secondary evaluations of MTA 36-month outcomes: propensity score and growth mixture model analyses. J Am Acad Child Adolesc Psychiatry 46(8):1003-1014 (Pubitemid 47220684)
23. Kilian R, Angermeyer MC (2005) The effects of antipsychotic treatment on quality of life of schizophrenic patients under naturalistic treatment conditions: an application of random effect regression models and propensity scores in an observational prospective trial. Qual Life Res 14:1275-1289 (Pubitemid 40895750)
24. D'Agostino RB (1998) Tutorial in biostatistics. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 17:2265-2281
25. Greene WH (2003) Econometric analysis, 5th edn. Prentice Hall, Upper Saddle River
26. Erdfelder E, Buchner A, Faul F et al (2004) GPower Teststa ̈rkeanalysen leicht gmeacht. In: Erdfelder E, Funke J (eds) Allgemeine Psychologie und Deduktivistische Methodologie. Vandenhoeck & Ruprecht, Göttingen, pp 148-166
27. Barbui C, Nose M, Mazzi MA et al (2006) Persistence with polypharmacy and excessive dosing in patients with schizophrenia treated in four European countries. Int Clin Psychopharmacol 21(6):355-362 (Pubitemid 44498277)
28. Constantine RJ, Andel R, Tandon R (2010) Trends in adult antipsychotic polypharmacy: progress and challenges in Florida's Medicaid program. Community Ment Health J
29. Messer T, Tiltscher C, Schmauss M (2006) Polypharmacy in the treatment of schizophrenia. Fortschr Neurol Psychiatry 74(7):377-391 (Pubitemid 44098009)
30. Mojtabai R, Olfson M (2010) National trends in psychotropic medication polypharmacy in office-based psychiatry. Arch Gen Psychiatry 67(1):26-36
31. Procyshyn RM, Honer WG, Wu TK et al (2010) Persistent antipsychotic polypharmacy and excessive dosing in the community psychiatric treatment setting: a review of medication profiles in 435 Canadian outpatients. J Clin Psychiatry 71(5):566-573
32. Rupnow MF, Greenspan A, Gharabawi GM et al (2007) Incidence and costs of polypharmacy: data from a randomized, double-blind, placebo-controlled study of risperidone and quetiapine in patients with schizophrenia or schizoaffective disorder. Curr Med Res Opin 23(11):2815-2822 (Pubitemid 350146419)
33. Zink M, Englisch S, Meyer-Lindenberg A (2010) Polypharmacy in schizophrenia. Curr Opin Psychiatry 23(2):103-111